LifeTech Scientific (HKG:1302) said its heart implant was admitted into China's fast-track approval pathway, according to a Hong Kong bourse filing Friday.
The device -- a congenital heart defect occluder designed to treat patent ductus arteriosus -- was accepted into a National Medical Products Administration program for innovative medical devices.
The inclusion is expected to shorten the registration process and speed up the product's launch, the company said.